Osteoporosis and Dental Implant (OPOZAHN)
Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Dieter Felsenberg, Prof. Dr.
- Phone Number: +490384453046
- Email: dieter.felsenberg@charite.de
Study Contact Backup
- Name: Hendrikje Boerst, Dipl. Wiss org.
- Phone Number: +490384454745
- Email: hendrikje.boerst@charite.de
Study Locations
-
-
-
Berlin, Germany, 12200
- Recruiting
- Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin
-
Contact:
- Dieter Felsenberg, Prof. Dr.
- Phone Number: +493084453046
-
Contact:
- Hendrikje Boerst, Dipl. Wiss. org.
- Phone Number: +493084454745
- Email: hendrikje.boerst@charite.de
-
Principal Investigator:
- Dieter Felsenberg, Prof. Dr.
-
Sub-Investigator:
- Anton ° Friedman, Dr.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postmenopausal women > 2 years after menopause
- Age between 60 and 75 years
- Possibility to insert a dental implant
- Osteoporosis as defined by WHO criteria (intervention group), or women without osteoporosis / osteopenia (non-intervention group)
Exclusion Criteria:
- Pathological findings in the jaw bone
- Chronic inflammatory rheumatoid disease
- Bisphosphonate treatments during the last 12 months
- Inflammatory or metabolic bone disease, excluding osteoporosis
- Systemic corticosteroid treatments of more than one month within previous 12 months
- Severe diseases with life expectancy less than one year or expectation of rapid worsening within one year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
|
alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
|
|
Placebo Comparator: 2
placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
|
placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
|
|
No Intervention: 3
dental implant, calcium 1000mg and Vitamin D 800 IU daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dental CT
Time Frame: baseline, and 3,6,12 months after baseline
|
baseline, and 3,6,12 months after baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Dieter Felsenberg, Prof. D.r, Leader of the center for muscle and bone research, Charité
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OPOZAHN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.